JM
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
9
2 agencies contacted
Activity
filings by quarter
Works on
Specific issues
Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability of access for patients to generic and biosimilar medicines H.R.1503/S.2916: Prescription Information Modernization Act of 2023 H.R.2880: Protecting Patients Against PBM Abuses Act H.R.5429/S.2780: Medication Affordability and Patent Integrity Act 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024 Lower Costs, More Transparency Act (H.R. 5378) H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act S.2305: Biosimilar Red Tape Elimination Act Appropriations pertaining to American Made preference for generic products Issues related to Medicaid Generics Penalty Issues related to the IRA Issues related to drug supply chain Senate Finance Committee drug shortage legislation Proposals related to drug shortages
Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability of access for patients to generic and biosimilar medicines Lower Costs, More Transparency Act (H.R. 5378) H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023 H.R.1352: Increasing Access to Biosimilars Act of 2023 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 Senate Finance Committee drug shortage legislation Appropriations pertaining to American Made preference for generic products Issues related to Medicaid Generics Penalty Issues related to DEA Quota Issues related to drug supply chain
Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability for accessible medicines
Issues related to accessible medicines; marketplace issues; Issues related to economics of manufacturing essential medicines.